UBS raised the firm’s price target on Owens & Minor to $27 from $26 and keeps a Buy rating on the shares. Owens & Minor’s updated guidance requires a relatively steep sequential EPS ramp in 2024 and growth acceleration in 2025 and beyond to hit existing 2028 targets, the analyst tells investors in a research note. The firm is incrementally cautious on the near-term but still believes its long-term theses on personal protective equipment turnaround and Patient Direct momentum hold true.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OMI: